Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy—results from the prospective multi-center BRENDA II study

Elena Leinert1· Lukas Schwentner1 · Wolfgang Janni1 · Achim Wöckel2 · Saskia-L. Herbert2 · Daniel Herr2 · Thorsten Kühn3 · Felix Flock4 · Ricardo Felberbaum5 · Rolf Kreienberg1 · Visnja Fink1 · Davut Dayan1 · Kristina Ernst1 · Susanne Singer6 on behalf of the BRENDA study group

Received: 31 May 2021 / Accepted: 1 December 2021 / Published online: 18 February 2022
© The Author(s) 2022

Abstract

Background This study examined 5-year overall, recurrence and distant metastasis-free survival (OS, RFS, MFS) of high- and intermediate-risk breast cancer (BC) patients who declined guideline-recommended adjuvant chemotherapy (CHT).

Methods In the prospective multicenter cohort study BRENDA II, patients with primary BC were sampled over a period of four years (2009–2012). A multi-professional team (tumorboard) discussed recommendation for adjuvant CHT according to the German guideline. Potential differences in 5-year survival were analyzed using Kaplan–Meier curves and Cox regression. The hazard ratios (HR) were adjusted for age, Charlson Comorbidity Score, American Society of Anesthesiologist (ASA) physical status classification, and endocrine therapy.

Results A total of 759 patients were enrolled of which 688 could receive CHT according to the guidelines (n = 219 had a clear indication, in n = 304 it was possible). For 360 patients, the tumorboard advised to perform CHT, for 304 it advised against and in 24 cases, no decision was documented. Of those with a positive suggestion, 83% received CHT. Until 5 years after diagnosis, 57 patients were deceased, 41 had at least one distant metastasis and 29 a recurrence. There was no evidence for differences in OS and MFS in patients who declined CHT despite tumorboard recommendation (HR 3.5, 95% CI 0.8–15.1 for OS, HR 1.9, 95% 0.6–6.6 for MFS). Patients who received CHT had significantly better 5-year RFS compared to those who declined (HR 0.3, 95% CI 0.1–0.9, p = 0.03). There was no evidence for different survival in those who had no CHT because of comorbidity and those who declined actively, neither for OS, MFS nor RFS.

Conclusion The prospective BRENDA II study demonstrates benefit in RFS by guideline adherence in adjuvant breast cancer treatment, indicating prospectively the value of internationally validated guidelines in breast cancer care.

Keywords Breast cancer · Guideline adherence · Guideline violation · Adjuvant chemotherapy

Authors are the members of the BRENDA study group.
Introduction

Women with primary diagnosis of early breast cancer (BC) all in all have a favorable prognosis with good survival rates [1]. Consensus recommendations and guidelines such as the St. Gallen international expert consensus and the German interdisciplinary S3 guideline on diagnosis and treatment of BC were implemented to standardize adjuvant BC therapy and to improve the quality of care [2, 3]. Previous retrospective studies could demonstrate that patients with guideline-adherent adjuvant treatment will have better OS and DFS compared to patients with guideline violations [4–6]. Nevertheless, some patients may decline the recommended standard treatments and are consequently not treated according to guidelines. Regarding CHT, basically two groups can be distinguished among patients who are not treated guideline conform: on the one side, patients with comorbidities or elderly patients who are not accessible for CHT [7] and on the other side, patients that are eligible for CHT but who decline by themselves. However, this second group of patients is the only one for which the decision against CHT could be modified [8, 9]. Therefore, the aim of the prospective BRENDA II study was to assess these patient-related factors that prevent patients from receiving guideline-adherent treatment. Thus, this study aims to answer the following questions:

1. Among BC patients for whom adjuvant CHT is indicated and for whom the tumorboard recommends CHT, do those who do not receive CHT because they decline have worse outcome than those who receive it (after adjusting for comorbidities)?
2. Does the reason for omission of CHT (comorbidities, patient declines herself) make a difference regarding the outcome (in terms of OS, RFS and MFS, adjusted for age)?

Patients and methods

Data Collection

In the prospective multicenter cohort study BRENDA II (“Breast Cancer under Evidence-Based Guidelines”), patients with primary BC were sampled consecutively over a period of 4 years (2009–2012). Patients were approached before surgery (t1), before initiation of adjuvant treatment (t2), after completion of adjuvant radio- and/or CHT (t3), and contacted again 5 years after surgery (t4). Patients were eligible for this study if they had been diagnosed with primary histologically confirmed BC. Exclusion criteria were as follows: metastatic or recurrent disease at baseline (including secondary malignancies), bilateral BC, primary occult disease and phylloides tumor, inability to complete a questionnaire and no written informed consent. Each patient was informed about the study by her doctor and asked to participate. If she agreed, the doctor handed over the first series of questionnaires and interviewed the patient. Follow-up interviews were performed by trained study nurses. We collected data at the University Medical Center in Ulm, Kempten Hospital, Memminger Hospital and Esslingen Hospital, all of which are BC centers certified by the German Cancer Society. Ethical approval was obtained from the Ethics Committee of Ulm University. After surgery, a multi-professional team (tumorboard) consisting of gynecologic, medical, and radiation oncologists, BC surgeons, pathologists, radiologists, and study nurses discussed the recommendation for adjuvant CHT based on current validated guidelines and this decision was documented in a database. Six months later, it was documented whether the patient had received adjuvant CHT or declined.

Statistical analysis

Absolute and relative frequencies of treatment decisions regarding CHT and subsequent application of CHT were calculated overall and per institution. Survival time was defined as time between baseline (t1) until the event of interest (death, recurrence, distant metastasis) happened or until
end of follow-up. If a patient was lost to follow-up, data were censored at the date of the last known contact. Survival distributions and median survival times were estimated using the Kaplan–Meier product-limit method. The 5 year OS rate as well as RFS and MFS with 95% confidence interval (95% CI) were computed using Kaplan–Meier product-limit survival probabilities at the specified time points. Groups were compared using Cox proportional hazards models adjusted for age, Charlson Comorbidity Score, ASA, and endocrine therapy estimating the hazard ratio (HR) and 95% confidence intervals. The proportional hazards assumption was tested using log–log plot and predicted survival plots. Statistical analyses were performed using STATA 12 (StataCorp 2011, College Station, TX, USA: StataCorp LP).

Results

Altogether, 759 patients with primary BC were included in the study. Based on the St. Gallen (2007) criteria and guideline recommendations, 219 patients had clear indication for CHT (high-risk patients), among them 100 patients with Her2-positive BC. A total of 469 patients were intermediate-risk patients, for whom it was possible but not mandatory to recommend adjuvant CHT (Fig. 1). 71 patients were excluded because they had no indication for CHT or indication was unclear. Thus, the entire sample included 688 patients.

We found locally advanced BC (≥ T2, N1) in 65% of the patients (Table 1). 80% of the patients were hormone receptor positive and consequently eligible for endocrine treatment. The tumorboard decision was in favor of CHT in 360 patients (among them 188 high-risk patients and 172 intermediate-risk patients). In 304 of the cases (44%), the tumorboard recommendation was against CHT (20 high-risk patients and 284 at intermediate risk). This proportion differed between centers: the tumorboard decided against CHT in 48%, 37%, 30%, and 33% of the patients (p<0.001).

Among those patients with a tumorboard recommendation in favor of CHT, 299 patients eventually received CHT (83%) and 61 patients (17%) declined (Fig. 1). There was no evidence that this proportion differed between the centers (19%, 9%, 14%, and 6% respectively declined; p = 0.19). The proportion of patients who did not receive CHT despite tumorboard recommendation was higher in intermediate-risk patients than in high-risk patients (27% vs. 7%).

Among the patients without a tumorboard recommendation in favor of CHT, 96% of the patient did not receive CHT and 12 patients still received CHT, all of them belonged to the group of high-risk-patients. Of the 219 high-risk patients, 30 (14%) deceased during the follow-up period. The proportion of lethal events in the intermediate-risk group was 6%.

For further analysis, all patients (high- and intermediate-risk) with a tumorboard recommendation in favor of CHT

![Fig. 1 Patient flow through the study](image-url)
were combined \( (n = 360) \). After adjusting for age, ASA score, Charlson Comorbidity index, and endocrine treatment, we found a significant benefit regarding 5 year RFS for patients who received CHT (HR 0.3, 95% CI 0.1–0.9, \( p = 0.03 \)) (Table 2). There was no evidence for differences in OS between patients who received or declined CHT if it was recommended by the tumorboard (HR 3.5, 95% CI 0.8–15.1, \( p = 0.09 \)). There was also no evidence for differences in MFS (HR 2.9, 95% CI 0.4–22.6) (Fig. 2).

Another analysis considered patients who did not receive CHT even though it was indicated or possible according to guidelines \( (n = 353) \). Among them, 22 were high-risk patients. 61 of 353 patients had a recommendation in favor of CHT, but they declined; and in 292 patients, the tumorboard recommended no CHT. Overall, after adjusting for potential confounding factors (age, ASA score, Charlson Comorbidity index, endocrine treatment), there was no evidence for differences in OS, RFS or MFS between those who declined CHT by themselves and those where the tumorboard had advised against CHT. The proportion of deaths was 3% if CHT was recommended by the tumorboard but the patient declined vs. 8% if no CHT had been recommended \( [HR for OS 0.6 (95% CI 0.1–2.6), \ p = 0.50] \) (Table 3). Of the high risk BC patients who did not receive CHT because the tumorboard voted against it, 38% deceased during the follow-up period (Table 4).

**Discussion**

BC remains a challenge for clinical oncologist, as it represents the most common malignancy in women. Beside operative therapy, radiotherapy and endocrine treatment, CHT is often one essential part of the treatment in early BC setting. The multidisciplinary tumorboard selects the appropriate treatment strategy considering the guidelines on the basis of a risk assessment for each individual patient, in order to avoid both over- and undertreatment regarding CHT. The tumorboard also considers further patient-related factors like age, comorbidities and cognitive impairment. Previous studies could demonstrate that if one or multiple of these factors are constricted, patients will have a higher risk of not receiving guideline-adherent treatment. This finally leads

---

**Table 1** Baseline characteristics of the study population \( (n = 688) \)

| Age at diagnosis in years | \( n \) | Percent |
|---------------------------|------|---------|
| <40                       | 39   | 6%      |
| 40–49                     | 146  | 21%     |
| 50–59                     | 190  | 28%     |
| 60–69                     | 187  | 27%     |
| 70–79                     | 107  | 16%     |
| 80+                       | 19   | 3%      |
| Year of diagnosis         |      |         |
| 2008                      | 19   | 3%      |
| 2009                      | 139  | 20%     |
| 2010                      | 215  | 31%     |
| 2011                      | 311  | 45%     |
| 2012                      | 3    | 0.4%    |
| Locally advanced \( (>= T2, N1) \) |      |         |
| No                        | 244  | 35%     |
| Yes                       | 444  | 65%     |
| ASA (at baseline)         |      |         |
| I                         | 130  | 19%     |
| II                        | 403  | 59%     |
| III                       | 137  | 20%     |
| IV                        | 2    | 0.3%    |
| Unknown                   | 16   | 2%      |
| Charlson comorbidity Index (at baseline) |      |         |
| 0                         | 480  | 70%     |
| 1                         | 97   | 14%     |
| 2                         | 46   | 7%      |
| 3                         | 9    | 1%      |
| 4                         | 10   | 1%      |
| 5                         | 4    | 1%      |
| 6                         | 10   | 1%      |
| 8                         | 3    | 0.4%    |
| Unknown                   | 29   | 4%      |
| Hormone receptor          |      |         |
| Negative                  | 139  | 20%     |
| Positive                  | 549  | 80%     |
| Her2-status               |      |         |
| Negative                  | 588  | 85%     |
| Positive                  | 100  | 15%     |
Fig. 2  5 year overall survival, metastasis-free survival, and recurrence-free survival in patients with tumorboard recommendation in favor of chemotherapy. Hazard Ratio (HR) adjusted for age, ASA score, Charlson Comorbidity index, endocrine treatment
to decreased OS [12–15]. Unfortunately, the reasons why CHT was not recommended by the tumorboard could not be evaluated in this study because of incomplete data. Nevertheless, we suppose that for high-risk patients for whom the tumorboard did not recommend CHT (n = 20), the main reasons for omission of CHT were age and/or comorbidities. On the other hand, there is a group of patients (in our cohort 17% both in the high and intermediate risk group), for whom CHT was recommended by the tumorboard but they declined. In the literature, we could find similar rates for both high and intermediate-risk patients who decline CHT [16]. For high-risk patients only, the rate of deviation from CHT was 7% in our cohort, which is also conform to other studies [17]. The proportion of patients who did not receive CHT despite recommendation in favor of CHT was higher in intermediate-risk patients than in high-risk patients. This is most likely due to two reasons: first, we assume that the physician recommends CHT more urgently in high-risk patients and second, patients with intermediate risk BC will have the option to receive endocrine treatment. It is known from other studies that fear of CHT-related side effects is the main reason for omission of CHT from the patient’s point of view [18]. In contrast to age and comorbidities, fear of the treatment would be a modifiable factor to improve treatment adherence. In this regard, more extensive studies would be required to investigate the factors for omission of CHT. In our cohort of high and intermediate risk BC patients, we could find improved RFS after adjuvant CHT but, surprisingly, we could not demonstrate a survival benefit if CHT was applied. There may be multiple reasons for this result, which is opposite to other studies in early BC setting [19]. One reason may be the very high survival rate in our cohort anyways and with the limited number of cases, a benefit of CHT potentially could not be demonstrated. Particularly in the light of the high proportion of patients with luminal tumors, the follow-up period of 5 years

| Table 3 | In intermediate and high-risk patients who did not receive chemotherapy (n = 353) |
| Probability of | Hazard ratioa | 95% CI | p value |
| Death | 0.6 | (0.1–2.6) | 0.50 |
| Metastasis | 1.5 | (0.4–6.3) | 0.56 |
| Recurrence | 2.1 | (0.6–7.5) | 0.25 |

Table 4: Number and proportion of events in the study population (a) overall (b) high-risk patients (c) intermediate-risk patients

(a) Overall

| Tumorboard decision | Pro CHT (n=360) | Contra CHT (n=304) | No decision documented (n=24) | Total |
|----------------------|-----------------|-------------------|-----------------------------|-------|
| CHT received | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No |
| # patients | 299 | 61 | 12 | 292 | 15 | 9 | 688 |
| # dead | 28 (9%) | 2 (3%) | 1 (8%) | 23 (8%) | 1 (7%) | 2 (22%) | 57 |
| # metastasis | 24 (8%) | 4 (7%) | 2 (17%) | 9 (3%) | 2 (13%) | 0 (0%) | 41 |
| # recurrence | 14 (5%) | 6 (10%) | 1 (8%) | 7 (2%) | 1 (7%) | 0 (0%) | 29 |

(b) High-risk patients

| Tumorboard decision | Pro CHT (n=188) | Contra CHT (n=20) | No decision documented (n=11) | Total |
|----------------------|-----------------|------------------|-----------------------------|-------|
| CHT received | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No |
| # patients | 174 | 14 | 12 | 8 | 8 | 3 | 219 |
| # dead | 23 (13%) | 1 (7%) | 1 (8%) | 3 (38%) | 1 (13%) | 1 (33%) | 30 (14%) |

(c) Intermediate-risk patients

| Tumorboard decision | Pro CHT (n=172) | Contra CHT (n=284) | No decision documented (n=13) | Total |
|----------------------|-----------------|-------------------|-----------------------------|-------|
| CHT received | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No |
| # patients | 125 | 47 | 0 | 284 | 7 | 6 | 469 |
| # dead | 5 (4%) | 1 (2%) | 0 | 20 (7%) | 0 | 1 (17%) | 27 (6%) |

CHT chemotherapy

Springer
is rather short as relapse often occurs after a longer period [20]. Besides, long-term toxic effects of adjuvant CHT like CHT-induced cardiotoxicity were not considered. Benefits of CHT may be partially obfuscated by adverse effects on the cardiovascular system, resulting in a significant increase in morbidity and mortality [21]. And finally, to our opinion, the main reason is the fact that there were many patients at intermediate-risk in our cohort. For these patients, the rate of recommendation in favor of CHT in our study population was rather high (36%). Nowadays, indication for CHT in primary BC patients depends on intrinsic breast cancer subtype classification as well as clinical parameters such as grading, tumor size or nodal status [22, 23]. However, the data of our study were collected before the era of intrinsic breast cancer subtypes [24]. In a retrospective analysis by Herr et al. on 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer within the BRENDA study, adjuvant CHT in addition to endocrine therapy was not able to improve RFS and tumorspecific OS [25]. Furthermore, Herr et al. demonstrated that tumor size as well as nodal status was not predictive for a benefit of adjuvant CHT in the BRENDA cohort. This is important to note because these parameters were also used for our study population within the framework of the St. Gallen criteria. In the past decade, the use of adjuvant CHT in early BC setting in general decreased [26]. The introduction of gene expression signatures was an important milestone in the treatment intermediate risk BC patients. For that group, studies reported a 20–35% reduction in CHT administration with usage of gene expression signatures [27–29]. On the basis of recent studies, the indication for CHT is increasingly shifting to high-risk BC patients [30]. Thus, one might suspect that if only high-risk patients and patients at intermediate risk with high risk of recurrence had received adjuvant CHT, a survival benefit in the CHT group perhaps could have been demonstrated within the BRENDA study.

In summary, our data provide that patients with high- and intermediate-risk BC have an excellent prognosis and it is the first prospective study demonstrating RFS benefit by guideline adherence in adjuvant breast cancer treatment. This emphasizes the value of internationally validated guidelines in breast cancer care.

Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported by the German Federal Ministry of Education and Research (BMBF-Grant-01ZP0505).

Declarations

Conflict of interest Susanne Singer has received a research grant from Pfizer, the quality of life prize from Lilly, travel grants from Genzyme, and lecture fees from Astra Zeneca, Pfizer, Bristol-Myers Squibb, and Boehringer Ingelheim. The other authors declare that they have no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2003;8(6):541–52. https://doi.org/10.1634/theoncologist.8-6-541.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ; 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 2007;18(7):1133–44. https://doi.org/10.1093/annonc/mdm271.
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1,2018 AWMF Registernummer: 032-045OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
4. Schwentner L, Van Ewijk R, Kurzeder C, Hoffmann I, König J, Kreienberg R, et al. Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients. Eur J Cancer. 2013;49(3):553–63. https://doi.org/10.1016/j.ejca.2012.08.011.
5. Wollschlager D, Meng X, Wockel A, Janni W, Kreienberg R, Blettner M, et al. Comorbidity-dependent adherence to guidelines and survival in breast cancer—is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients. Breast. 2018;24(2):120–7.
6. Ebner F, van Ewijk R, Wockel A, Hancke K, Schwentner L, Fink V, et al. Tumor biology in older breast cancer patients—what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients. Breast (Edinburgh, Scotland). 2015;24(3):256–62.
7. Witherby SM, Muss HB. Special issues related to breast cancer adjuvant therapy in older women. Breast. 2005;14(6):600–11. https://doi.org/10.1016/j.breast.2005.08.015 (Epub 2005 Sep 29 PMID: 16198568).
8. Takasugi M, Iwamoto E, Akashi-Tanaka S, Kinoshita T, Fukutomi T, Kubouchi K. General aspects and specific issues of
informed consent on breast cancer treatments. Breast Cancer. 2005;12(1):39–44. https://doi.org/10.2325/jbcs.12.39 (PMID: 15657522).

9. Degner LF, Kristjanson LJ, Bowman D, Sloan JA, Carriere KC, O’Neil J, et al. Information needs and decisional preferences in women with breast cancer. JAMA. 1997;277(18):1485–92 (PMID: 9145723).

10. D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson Comorbidity Index. Methods Inf Med. 1993;32:382–7.

11. Wolters R, Regierer AC, Schwentner L, Geyer V, Posssinger K, Kreienberg R, et al. A comparison of international breast cancer guidelines—do the national guidelines differ in treatment recommendations? Eur J Cancer. 2012;48(1):1–11.

12. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21:3580–7.

13. Schwentner L, Van Ewijk R, Kühn T, Flock F, Felberbaum R, Blettner M, et al. Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II. Support Care Cancer. 2016;24(6):2759–66.

14. Leinert E, Singer S, Janni W, Harbeck N, Weißenbacher T, Rack B, et al. The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy: a comparative analysis from the prospective multicenter randomized ADEBAR trial. Clin Breast Cancer. 2017;17(2):100–6. https://doi.org/10.1016/j.clbc.2016.10.008.

15. Leinert E, Schwentner L, Blettner M, Wöckel A, Felberbaum R, Flock F, et al. Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: results from the prospective multicenter BRENDA II study. Breast J. 2019;25(3):386–92. https://doi.org/10.1111/1321-332X.13231.

16. Ho PJ, Ow SGW, Sim Y, et al. Impact of deviation from guideline recommended treatment on breast cancer survival in Asia. Sci Rep. 2020;10:1330. https://doi.org/10.1038/s41598-020-58007-5.

17. Oruccevic A, Heidel RE, Bell JL. (2018) Outcomes of patients with invasive breast cancer (IBC) refusing standard cancer treatments: 10-year analysis of the National cancer data base (NCDB) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5–9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res. 78(4 Suppl);Abstract nr P6-08-19.

18. Singer S, Blettner M, Kreienberg R, Janni W, Wöckel A, Kühn T, et al. Breast cancer patients’ fear of treatment: results from the multicenter longitudinal study BRENDA II. Breast Care (Basel). 2015;10(2):95–100. https://doi.org/10.1159/000381933.

19. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Petro R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44. https://doi.org/10.1016/S0140-6736(11)61625-5 (Epub 2011 Dec 5).

20. van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer. 2019;144(2):263–72. https://doi.org/10.1002/ijc.31914.

21. Avila MS, Siqueira SRR, Ferreira SMA, Bocchi EA. Prevention and treatment of chemotherapy-induced cardiotoxicity. Methodist DeBakey Cardiovasc J. 2019;15(4):267–73. https://doi.org/10.14797/mdcj-15-4-267.

22. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26-35. https://doi.org/10.1016/j.brest.2015.07.008 (Epub 2015 Aug 5).

23. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. https://doi.org/10.1038/35021093 (Epub 2000/08/30).

24. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25(10):1239–46. https://doi.org/10.1200/JCO.2006.07.1522. Erratum. In: J Clin Oncol. 2007 Aug 20;25(24):3790.

25. Herr D, Wischnewsky M, Joukhadar R, Chow O, Janni W, Leinert E, et al. Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multi-center Study. PLoS One. 2019;14(7): e0218434. https://doi.org/10.1371/journal.pone.0218434.

26. Matikas A, Foukakis T, Swain S, Bergh J. Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? Ann Oncol. 2019;30(7):1044–50. https://doi.org/10.1093/annonc/mdz126.

27. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21. https://doi.org/10.1056/NEJMoa1804710 (Epub 2018 Jun 3).

28. Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delalogue S, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2018;375(8):717–29. https://doi.org/10.1056/NEJMoa1602253.

29. Martin M, Brase JC, Calvo L, Krappmann K, Ruiz-Borrego M, Fisch K, et al. Clinical validation of the EndoPredict test in node-negative, chemotherapy-treated ER+/HER2—breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res. 2014;16(2):R38. https://doi.org/10.1186/bcr3642.

30. Kalinsky K, Barlow WE, Meric-Bernstam F, et al. (2020) First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1–3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2–) breast cancer (BC) with recurrence score (RS) ≤ 25: SWOG S1007 (RxPonder). Presented at: 2020 San Antonio Breast Cancer Symposium; December 8–11; virtual. Abstract GS3-00. https://www.abstractsonline.com/pp8/#/9223/presentations/rxponder/1

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.